Texas Pharmacy Shut Out of Controlled Substances by DEA
Published Date: 4/1/2025
Notice
Summary
Baijes Bissonnet Pharmacy in Texas tried to get a DEA registration but got denied because they filled risky prescriptions without fixing warning signs. They missed the deadline to ask for a hearing, so the DEA’s decision stands. This means the pharmacy can’t legally handle certain controlled medicines, affecting their business and customers right away.
Analyzed Economic Effects
4 provisions identified: 0 benefits, 4 costs, 0 mixed.
Baijes Bissonnet Pharmacy Registration Denied
Baijes Bissonnet Pharmacy's application for a DEA Certificate of Registration (Control No. W22147152A) is denied. The denial is effective May 1, 2025, and the Order also denies any other pending DEA registration application by Baijes Bissonnet Pharmacy in Texas.
Patients Lose Controlled-Med Access At Pharmacy
Customers who rely on Baijes Bissonnet Pharmacy in Stafford, Texas may no longer be able to obtain controlled-substance prescriptions there after May 1, 2025 because the pharmacy's DEA registration application was denied. The Order follows findings that the pharmacy repeatedly filled controlled-substance prescriptions with multiple red flags from at least March 2021 through August 2022.
Filling Red-Flag Prescriptions Risks Registration
The DEA found that repeatedly filling controlled-substance prescriptions that contained red flags (for example: pattern prescribing, cash payments, long-distance patients, and drug ‘cocktails’) supports denial of DEA registration. The Agency relied on factual findings including that 492 of 575 controlled-substance prescriptions (85%) were paid in cash and that 42 prescriptions to six individuals were essentially identical.
Missing Hearing Deadline Can Cause Default
The DEA deemed the applicant in default because it did not file a timely hearing request after being served the Order to Show Cause on December 19, 2023; the 30-day deadline for a hearing request ran to January 18, 2024. A default is deemed a waiver of the right to a hearing and an admission of the OSC allegations, which supported the Agency's request for final action.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11526, Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment
Starting July 9, 2026, new rules make it easier for doctors and pharmacies to provide medicine that helps people recover from opioid addiction. These changes affect healthcare providers by expanding who can give medication-assisted treatment and how pharmacies can deliver these medicines. The goal? Faster, safer access to treatment with clear rules that save time and support recovery.
2026-10128, Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2025-05007, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
Starting December 31, 2025, veterans can get buprenorphine treatment and follow-up care through telemedicine, making it easier to access help for opioid use disorder without leaving home. This change affects veterans using VA health services and aims to improve treatment access while the government reviews feedback and policies. No new costs are mentioned, but the delay gives agencies time to ensure the rules work well.
2025-02793, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
The government is giving veterans easier access to buprenorphine treatment through telemedicine, letting them get care remotely. This change affects veterans using VA health services and aims to make treatment smoother and more convenient. The new rules were supposed to start February 18, 2025, but now they’ll kick in on March 21, 2025, while the government gathers public feedback.
2026-22843, Proposed Aggregate Production Quotas for Schedule I and II Controlled Substances and Assessment of Annual Needs for the List I Chemicals Ephedrine, Pseudoephedrine, and Phenylpropanolamine for 2027
The DEA is setting limits on how much of certain controlled drugs and chemicals can be made in 2027. This affects drug makers and anyone involved in producing or handling these substances. They’re asking for public comments by December 10, 2026, before finalizing the amounts, which helps keep drug supply safe and balanced.
2026-22842, Adjustment to the 2026 Aggregate Production Quota for d,l-Amphetamine, d-Amphetamine (for Sale), Hydromorphone and Methylphenidate (for Sale) Pursuant to 21 U.S.C. 826(h)
The DEA is boosting the 2026 production limits for four important medicines: d,l-amphetamine, d-amphetamine (for sale), hydromorphone, and methylphenidate (for sale). This change helps fix shortages and keeps medicines flowing smoothly. The new quotas take effect right away on November 10, 2026, so manufacturers can ramp up production without delay.
Previous / Next Documents
Previous: 2025-05526, Phong H. Tran, M.D.; Decision and Order
The DEA has officially denied Dr. Phong H. Tran’s application to register for handling controlled substances in California because he’s excluded from federal health programs and lacks state permission. This means Dr. Tran can’t legally prescribe or manage certain drugs, impacting his medical practice and patients. The decision is final as of April 1, 2025, and no appeals were filed.
Next: 2025-05528, Mary Massullo, D.O.; Decision and Order
Mary Massullo, D.O., lost her license to handle controlled substances because she no longer has permission from Ohio, where she’s registered. She didn’t ask for a hearing, so the DEA decided to revoke her registration officially. This means she can’t legally work with controlled drugs anymore, and her registration expired on January 31, 2025.